224 related articles for article (PubMed ID: 32580836)
1. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
2. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Yeom DH; Lee YS; Ryu I; Lee S; Sung B; Lee HB; Kim D; Ahn JH; Ha E; Choi YS; Lee SH; You WK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383646
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
4. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.
Sun HW; Wu C; Tan HY; Wang QS
Hepatogastroenterology; 2012 May; 59(115):924-9. PubMed ID: 22020917
[TBL] [Abstract][Full Text] [Related]
5. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
Zhou R; Wang S; Wen H; Wang M; Wu M
Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
[TBL] [Abstract][Full Text] [Related]
6. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
[TBL] [Abstract][Full Text] [Related]
7. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
8. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
9. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
10. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
11. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
[TBL] [Abstract][Full Text] [Related]
12. Altered ratios of pro- and anti-angiogenic VEGF-A variants and pericyte expression of DLL4 disrupt vascular maturation in infantile haemangioma.
Ye X; Abou-Rayyah Y; Bischoff J; Ritchie A; Sebire NJ; Watts P; Churchill AJ; Bates DO
J Pathol; 2016 Jun; 239(2):139-51. PubMed ID: 26957058
[TBL] [Abstract][Full Text] [Related]
13. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo.
Mashima T; Wakatsuki T; Kawata N; Jang MK; Nagamori A; Yoshida H; Nakamura K; Migita T; Seimiya H; Yamaguchi K
Sci Rep; 2021 Jul; 11(1):15125. PubMed ID: 34302038
[TBL] [Abstract][Full Text] [Related]
15. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade.
Yamanda S; Ebihara S; Asada M; Okazaki T; Niu K; Ebihara T; Koyanagi A; Yamaguchi N; Yagita H; Arai H
Blood; 2009 Apr; 113(15):3631-9. PubMed ID: 19218547
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
17. Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
[TBL] [Abstract][Full Text] [Related]
18. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
Harrington LS; Sainson RC; Williams CK; Taylor JM; Shi W; Li JL; Harris AL
Microvasc Res; 2008 Mar; 75(2):144-54. PubMed ID: 17692341
[TBL] [Abstract][Full Text] [Related]
19. Influence of up-regulation of Notch ligand DLL4 on biological behaviors of human gastric cancer cells.
Li GG; Li L; Li C; Ye LY; Li XW; Liu DR; Bao Q; Zheng YX; Xiang DP; Chen L; Chen J
World J Gastroenterol; 2013 Jul; 19(28):4486-94. PubMed ID: 23901223
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
